Compare PCT & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | VOGX |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 556.5M | 482.8M |
| IPO Year | 2020 | 2026 |
| Metric | PCT | VOGX |
|---|---|---|
| Price | $1.80 | $12.47 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.40 | N/A |
| AVG Volume (30 Days) | ★ 8.0M | 73.8K |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,355,000.00 | N/A |
| Revenue This Year | $269.48 | N/A |
| Revenue Next Year | $262.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $12.61 |
| 52 Week High | $14.20 | $38.41 |
| Indicator | PCT | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 30.36 | 33.92 |
| Support Level | $1.60 | N/A |
| Resistance Level | $3.53 | $22.10 |
| Average True Range (ATR) | 0.33 | 2.36 |
| MACD | 0.02 | -0.60 |
| Stochastic Oscillator | 11.37 | 12.88 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.